Chemistry:Benzgalantamine
Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type.[1] It is a cholinesterase inhibitor.[1] Benzgalantamine is a prodrug of galantamine.[1]
The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]
Benzgalantamine was approved for medical use in the United States in July 2024.[1][2][3]
Medical uses
Benzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.[1][2]
Side effects
The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]
Society and culture
Legal status
Benzgalantamine was approved for medical use in the United States in July 2024.[1][2]
Names
Benzgalantamine is the international nonproprietary name.[4]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Cite error: Invalid
<ref>tag; no text was provided for refs namedZunveyl FDA label - ↑ 2.0 2.1 2.2 fda.gov
- ↑ "Alpha Cognition's Oral Therapy Zunveyl Receives FDA Approval to Treat Alzheimer's Disease" (Press release). Alpha Cognition. 29 July 2024. Archived from the original on 4 August 2024. Retrieved 4 August 2024 – via Business Wire.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information 36 (3). 2022.
External links
- "Benzgalantamine (Code C188656)". https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C188656.
 |  |
